

Nonclinical Drug Development of anti-achondroplasia therapy for activated FGFR3 inhibition with NPR-B-Targeting Peptide



OTHERS	Non-Clinical
Product Type	Biological-Peptide (<5kDa)
Indication	Achondroplasia
Target	Natriuretic peptide receptor B (NPR-B)
MoA(Mechanism of Action)	Restore chondrogenesis through its binding to the natriuretic peptide receptor B (NPR-B), resulting in the inhibition of downstream signaling pathways of the overactive FGFR3.
Competitiveness	Best in Class, Better pharmacokinetic profiles and potency
Development Stage	Non-Clinical
Route of Administration	Parenteral-Subcutaneous